Clinical Scorecard: B antigen transfusions may raise allergy risk
At a Glance
Category
Detail
Condition
Allergic transfusion reactions (ATRs)
Key Mechanisms
Association of B or AB plasma or platelets with increased ATR risk in blood type O patients in high alpha-gal syndrome prevalence areas.
Target Population
Patients with blood type O receiving blood transfusions.
Care Setting
Academic medical centers in regions with varying alpha-gal syndrome prevalence.
Key Highlights
Patients with blood type O receiving B or AB products had 3.93 times the risk of ATRs in high-prevalence areas.
Moderate to severe ATRs were 9.14 times more likely for blood type O patients receiving B products in high-prevalence clusters.
No excess ATRs were observed in low-prevalence clusters for blood type O patients receiving B, AB, or A products.
Guideline-Based Recommendations
Diagnosis
Monitor for allergic transfusion reactions in patients receiving B or AB products, especially in high AGS prevalence areas.
Management
Consider evaluating local reaction patterns and approaches to reduce risk from B antigen-containing products.
Monitoring & Follow-up
Track and report allergic transfusion reactions to improve understanding of risks associated with B and AB products.
Risks
Increased risk of ATRs associated with B or AB products in blood type O patients in high AGS prevalence regions.
Patient & Prescribing Data
Patients with blood type O undergoing transfusions.
B and AB products are associated with higher ATR risks in specific geographic areas.
Clinical Best Practices
Clinicians should be aware of the potential for increased ATRs when transfusing B or AB products to blood type O patients in high AGS prevalence areas.
Encourage reporting of allergic transfusion reactions to enhance data collection and risk assessment.
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
